Your session is about to expire
← Back to Search
Tamoxifen 20 mg for Tumors
Study Summary
This trial tests whether tamoxifen can help treat patients with neuroendocrine tumors that have progressed despite positive estrogen or progesterone expression.
- Tumors
- Neuroendocrine Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA sanctioned a dosage of 20 mg for Tamoxifen?
"Tamoxifen 20 mg safety has been partially studied in Phase 2 trials. Therefore, Power estimates the medication's security to be a score of two on a scale from one to three."
Are there any other experiments involving Tamoxifen 20 mg which have been conducted?
"Presently, 67 trials are running for Tamoxifen 20 mg. Of those studies, 22 have reached the Phase 3 stage. While Ann Arbor is the epicentre of these experiments, 7300 medical sites across America host them."
Is this medical investigation presently seeking participants?
"Yes, the clinicaltrials.gov database indicates that this medical study is actively recruiting patients. Launched on November 13th 2019 and last updated in October 2022, it seeks to involve 15 participants at a single site."
Could you please provide an estimate of the number of participants involved in this trial?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, which was initially posted on November 13th 2019, is currently enrolling patients; 15 participants need to be recruited from one medical centre."
What medical conditions is Tamoxifen 20 mg typically utilized to treat?
"Tamoxifen 20 mg is routinely prescribed for malignant neoplasms, but can also be utilized to address ovarian cancer and ovulation induction therapy among other high-risk conditions."
Share this study with friends
Copy Link
Messenger